Copyright Reports & Markets. All rights reserved.

Global Adalimumab Biosimilars Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Adalimumab Biosimilars
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Adalimumab Biosimilars Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 80mg
    • 1.3.3 40mg
    • 1.3.4 20mg
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Adalimumab Biosimilars Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Adult
    • 1.4.3 Child
  • 1.5 Global Adalimumab Biosimilars Market Size & Forecast
    • 1.5.1 Global Adalimumab Biosimilars Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Adalimumab Biosimilars Sales Quantity (2018-2029)
    • 1.5.3 Global Adalimumab Biosimilars Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Biotech
    • 2.1.1 Biotech Details
    • 2.1.2 Biotech Major Business
    • 2.1.3 Biotech Adalimumab Biosimilars Product and Services
    • 2.1.4 Biotech Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Biotech Recent Developments/Updates
  • 2.2 Hisun Pharmaceutical
    • 2.2.1 Hisun Pharmaceutical Details
    • 2.2.2 Hisun Pharmaceutical Major Business
    • 2.2.3 Hisun Pharmaceutical Adalimumab Biosimilars Product and Services
    • 2.2.4 Hisun Pharmaceutical Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Hisun Pharmaceutical Recent Developments/Updates
  • 2.3 Innovent Biologics
    • 2.3.1 Innovent Biologics Details
    • 2.3.2 Innovent Biologics Major Business
    • 2.3.3 Innovent Biologics Adalimumab Biosimilars Product and Services
    • 2.3.4 Innovent Biologics Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Innovent Biologics Recent Developments/Updates
  • 2.4 Fuhong Hanlin
    • 2.4.1 Fuhong Hanlin Details
    • 2.4.2 Fuhong Hanlin Major Business
    • 2.4.3 Fuhong Hanlin Adalimumab Biosimilars Product and Services
    • 2.4.4 Fuhong Hanlin Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Fuhong Hanlin Recent Developments/Updates
  • 2.5 China Biopharmaceuticals
    • 2.5.1 China Biopharmaceuticals Details
    • 2.5.2 China Biopharmaceuticals Major Business
    • 2.5.3 China Biopharmaceuticals Adalimumab Biosimilars Product and Services
    • 2.5.4 China Biopharmaceuticals Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 China Biopharmaceuticals Recent Developments/Updates
  • 2.6 Chia Tai Tianqing Pharmaceutical Group
    • 2.6.1 Chia Tai Tianqing Pharmaceutical Group Details
    • 2.6.2 Chia Tai Tianqing Pharmaceutical Group Major Business
    • 2.6.3 Chia Tai Tianqing Pharmaceutical Group Adalimumab Biosimilars Product and Services
    • 2.6.4 Chia Tai Tianqing Pharmaceutical Group Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments/Updates
  • 2.7 China Cell Engineering
    • 2.7.1 China Cell Engineering Details
    • 2.7.2 China Cell Engineering Major Business
    • 2.7.3 China Cell Engineering Adalimumab Biosimilars Product and Services
    • 2.7.4 China Cell Engineering Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 China Cell Engineering Recent Developments/Updates
  • 2.8 Suzhou Zhonghe Biomedical Technology
    • 2.8.1 Suzhou Zhonghe Biomedical Technology Details
    • 2.8.2 Suzhou Zhonghe Biomedical Technology Major Business
    • 2.8.3 Suzhou Zhonghe Biomedical Technology Adalimumab Biosimilars Product and Services
    • 2.8.4 Suzhou Zhonghe Biomedical Technology Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Suzhou Zhonghe Biomedical Technology Recent Developments/Updates
  • 2.9 Amgen
    • 2.9.1 Amgen Details
    • 2.9.2 Amgen Major Business
    • 2.9.3 Amgen Adalimumab Biosimilars Product and Services
    • 2.9.4 Amgen Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Amgen Recent Developments/Updates
  • 2.10 Sandoz
    • 2.10.1 Sandoz Details
    • 2.10.2 Sandoz Major Business
    • 2.10.3 Sandoz Adalimumab Biosimilars Product and Services
    • 2.10.4 Sandoz Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Sandoz Recent Developments/Updates
  • 2.11 Boehringer Ingelheim
    • 2.11.1 Boehringer Ingelheim Details
    • 2.11.2 Boehringer Ingelheim Major Business
    • 2.11.3 Boehringer Ingelheim Adalimumab Biosimilars Product and Services
    • 2.11.4 Boehringer Ingelheim Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.12 Mylan
    • 2.12.1 Mylan Details
    • 2.12.2 Mylan Major Business
    • 2.12.3 Mylan Adalimumab Biosimilars Product and Services
    • 2.12.4 Mylan Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Mylan Recent Developments/Updates
  • 2.13 Biogen
    • 2.13.1 Biogen Details
    • 2.13.2 Biogen Major Business
    • 2.13.3 Biogen Adalimumab Biosimilars Product and Services
    • 2.13.4 Biogen Adalimumab Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Biogen Recent Developments/Updates

3 Competitive Environment: Adalimumab Biosimilars by Manufacturer

  • 3.1 Global Adalimumab Biosimilars Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Adalimumab Biosimilars Revenue by Manufacturer (2018-2023)
  • 3.3 Global Adalimumab Biosimilars Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Adalimumab Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Adalimumab Biosimilars Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Adalimumab Biosimilars Manufacturer Market Share in 2022
  • 3.5 Adalimumab Biosimilars Market: Overall Company Footprint Analysis
    • 3.5.1 Adalimumab Biosimilars Market: Region Footprint
    • 3.5.2 Adalimumab Biosimilars Market: Company Product Type Footprint
    • 3.5.3 Adalimumab Biosimilars Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Adalimumab Biosimilars Market Size by Region
    • 4.1.1 Global Adalimumab Biosimilars Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Adalimumab Biosimilars Consumption Value by Region (2018-2029)
    • 4.1.3 Global Adalimumab Biosimilars Average Price by Region (2018-2029)
  • 4.2 North America Adalimumab Biosimilars Consumption Value (2018-2029)
  • 4.3 Europe Adalimumab Biosimilars Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Adalimumab Biosimilars Consumption Value (2018-2029)
  • 4.5 South America Adalimumab Biosimilars Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Adalimumab Biosimilars Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Adalimumab Biosimilars Sales Quantity by Type (2018-2029)
  • 5.2 Global Adalimumab Biosimilars Consumption Value by Type (2018-2029)
  • 5.3 Global Adalimumab Biosimilars Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Adalimumab Biosimilars Sales Quantity by Application (2018-2029)
  • 6.2 Global Adalimumab Biosimilars Consumption Value by Application (2018-2029)
  • 6.3 Global Adalimumab Biosimilars Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Adalimumab Biosimilars Sales Quantity by Type (2018-2029)
  • 7.2 North America Adalimumab Biosimilars Sales Quantity by Application (2018-2029)
  • 7.3 North America Adalimumab Biosimilars Market Size by Country
    • 7.3.1 North America Adalimumab Biosimilars Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Adalimumab Biosimilars Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Adalimumab Biosimilars Sales Quantity by Type (2018-2029)
  • 8.2 Europe Adalimumab Biosimilars Sales Quantity by Application (2018-2029)
  • 8.3 Europe Adalimumab Biosimilars Market Size by Country
    • 8.3.1 Europe Adalimumab Biosimilars Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Adalimumab Biosimilars Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Adalimumab Biosimilars Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Adalimumab Biosimilars Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Adalimumab Biosimilars Market Size by Region
    • 9.3.1 Asia-Pacific Adalimumab Biosimilars Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Adalimumab Biosimilars Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Adalimumab Biosimilars Sales Quantity by Type (2018-2029)
  • 10.2 South America Adalimumab Biosimilars Sales Quantity by Application (2018-2029)
  • 10.3 South America Adalimumab Biosimilars Market Size by Country
    • 10.3.1 South America Adalimumab Biosimilars Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Adalimumab Biosimilars Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Adalimumab Biosimilars Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Adalimumab Biosimilars Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Adalimumab Biosimilars Market Size by Country
    • 11.3.1 Middle East & Africa Adalimumab Biosimilars Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Adalimumab Biosimilars Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Adalimumab Biosimilars Market Drivers
  • 12.2 Adalimumab Biosimilars Market Restraints
  • 12.3 Adalimumab Biosimilars Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Adalimumab Biosimilars and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Adalimumab Biosimilars
  • 13.3 Adalimumab Biosimilars Production Process
  • 13.4 Adalimumab Biosimilars Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Adalimumab Biosimilars Typical Distributors
  • 14.3 Adalimumab Biosimilars Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Adalimumab Biosimilars market size was valued at USD 23870 million in 2022 and is forecast to a readjusted size of USD 31050 million by 2029 with a CAGR of 3.8% during review period.
    Adalimumab, as a fully human anti-tumor necrosis factor alpha (TNF-ɑ) monoclonal antibody, can specifically bind to soluble human TNF-ɑ and block its interaction with cell surface TNF receptors p55 and p75. Thereby effectively blocking the inflammatory effect of TNF-ɑ.
    The Global Info Research report includes an overview of the development of the Adalimumab Biosimilars industry chain, the market status of Adult (80mg, 40mg), Child (80mg, 40mg), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Adalimumab Biosimilars.
    Regionally, the report analyzes the Adalimumab Biosimilars markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Adalimumab Biosimilars market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Adalimumab Biosimilars market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Adalimumab Biosimilars industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., 80mg, 40mg).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Adalimumab Biosimilars market.
    Regional Analysis: The report involves examining the Adalimumab Biosimilars market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Adalimumab Biosimilars market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Adalimumab Biosimilars:
    Company Analysis: Report covers individual Adalimumab Biosimilars manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Adalimumab Biosimilars This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adult, Child).
    Technology Analysis: Report covers specific technologies relevant to Adalimumab Biosimilars. It assesses the current state, advancements, and potential future developments in Adalimumab Biosimilars areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Adalimumab Biosimilars market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Adalimumab Biosimilars market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    80mg
    40mg
    20mg
    Market segment by Application
    Adult
    Child
    Major players covered
    Biotech
    Hisun Pharmaceutical
    Innovent Biologics
    Fuhong Hanlin
    China Biopharmaceuticals
    Chia Tai Tianqing Pharmaceutical Group
    China Cell Engineering
    Suzhou Zhonghe Biomedical Technology
    Amgen
    Sandoz
    Boehringer Ingelheim
    Mylan
    Biogen
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Adalimumab Biosimilars product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Adalimumab Biosimilars, with price, sales, revenue and global market share of Adalimumab Biosimilars from 2018 to 2023.
    Chapter 3, the Adalimumab Biosimilars competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Adalimumab Biosimilars breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab Biosimilars.
    Chapter 14 and 15, to describe Adalimumab Biosimilars sales channel, distributors, customers, research findings and conclusion.

    Buy now